1Office for Cancer Screening National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital Chinese Academy
of Medical Sciences and Peking Union Medical College Beijing 100021 China
2Department of Comprehensive Oncology National Cancer
Center / National Clinical Research Center for Cancer / Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical
College Beijing 100021 China
3Gesi Hebei Medical Research Institute Shijiazhuang 065000 Hebei China
4
School of Public Health
Tianjin University of Traditional Chinese Medicine Tianjin 301617 China
Abstract：Objective To evaluate the adherence and influencing factors of colorectal cancer CRC patients using electronic
patient-reported outcome ePRO tool for symptom management during anti -tumor therapy. Method A retrospective analysis was
conducted on data of 326 CRC patients recruited from 36 hospitals nationwide from January to November 2023. Adherence to ePRO tool
during anti-tumor therapy was assessed using overall response rate ORR average response rate ARR single response rate SRR
and patient-level response rate PRR . The generalized linear mixed model was used to analyze factors influencing the use of ePRO
tool. Result During anti-tumor therapy ORR of CRC patients ranging from 31. 98% to 60. 36% and ARR from 31. 49% to 62. 09%
across different ePRO tool modules. The mean PRR of CRC patients varied between 27. 33% and 51. 15% depending on the total
number of treatment cycles. Higher adherence was observed in younger patients those with stage Ⅱ and Ⅲ CRC patients residing in
rural areas and those receiving immunotherapy. Conclusion Adherence to ePRO tools during anti-tumor therapy in CRC patients in
clinical settings is relatively low. To enhance the adherence of CRC patients to ePRO tools and thereby maximize their clinical utility in
symptom management efforts should be directed towards strengthening patient education optimizing the design of ePRO tools and
reinforcing the feedback mechanisms between healthcare providers and patients.
